BioCentury
ARTICLE | Finance

Un-Blended

Why Tarveda and its VCs are all-in on biologic-drug conjugates

February 1, 2016 8:00 AM UTC

A year after unveiling its Pentarin platform, Tarveda Therapeutics Inc. and its investors have seen enough data to exclusively focus the cancer company on its biologic-drug conjugates. Tarveda (formerly Blend Therapeutics Inc.) last week raised $38 million in a series C round and spun out its lead compound that was based on a different technology into an independent newco.

New investor Novo A/S and founding investor New Enterprise Associates led the round. Existing investors Flagship Ventures, NanoDimension and Eminent Venture Capital also participated. ...